With more than $7.3 million raised to date since it was launched almost a year ago, Campaign for our Future, is moving into Phase II. The Campaign, a major fundraising initiative serves to advance the ACT Program--Access to Care Today, Achieve a Cure Tomorrow. ACT is a comprehensive effort on behalf of NHF and includes a commitment to the following priorities:
 
• Government Awareness and Support
• Education for all Life Stages
• Access to Care at HTCs and Beyond
• Research and Training
• Strong Local Organizations.
 
Campaign for our Future has received support from all of NHF's stakeholders including corporate partners; NHF’s Medical and Scientific Advisory Committee (MASAC); individuals and families; associations and HTCs; and a 100% commitment from its Board of Directors and chapter network.
 
During the Opening Session at this year's Annual Meeting in San Francisco, October 29-31, 2009, NHF CEO, Val Bias, will provide an update on the Campaign as well as additional information about Phase II. 
 
Find out more or make a donation to the Campaign for Our Future.

The Visionary Corporate Partner and Lead Benefactor for the campaign is Novo Nordisk. Other sponsors are: Baxter, Principal Corporate Partner; Bayer, CSL Behring, and Wyeth, Major Corporate Partners; and Grifols, Corporate Partner.